Analyst Expectations For Celldex Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Celldex Therapeutics (NASDAQ:CLDX) over the past three months, with a majority being bullish. The average 12-month price target remains at $77.4. Despite financial challenges, including a significant revenue decline and negative net margins, the company shows strong ROE and ROA.
July 16, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target remains at $77.4. Despite a significant revenue decline and negative net margins, the company shows strong ROE and ROA.
The majority of analysts are bullish on CLDX, which is likely to positively impact the stock price in the short term. The consistent price target and strong ROE and ROA metrics further support a positive outlook despite financial challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100